Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves once-weekly dosing option for Kyprolis in relapsed or refractory multiple myeloma

Oct. 2, 2018

CHIT1 unveiled as a novel therapeutic target in IPF

Oct. 2, 2018

Patient recruitment ongoing in phase II study of PRCL-02 in chronic plaque psoriasis

Oct. 2, 2018

Kigabeq granted European marketing authorization

Oct. 2, 2018

Yervoy, Opdivo go to Stockholm: 2018 Medicine Nobel honors checkpoint inhibitor work

Oct. 2, 2018

Ocugen initiates the first trial in its phase III program of OCU-310 in dry eye disease

Oct. 2, 2018

Salk awarded CIRM grant to support development of immune-tolerant human islet-like organoids

Oct. 2, 2018

Mylan initiates phase III comparative study of MYL-1701P and Eylea

Oct. 2, 2018

Phase I study of Butantan Institute's H7N9 influenza antigen

Oct. 2, 2018

Patient recruitment is ongoing in phase II study of BI-730357 in plaque psoriasis

Oct. 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...